摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5-dimethyl-2-oxazolecarboxaldehyde | 65128-98-5

中文名称
——
中文别名
——
英文名称
4,5-dimethyl-2-oxazolecarboxaldehyde
英文别名
4,5-Dimethyl-1,3-oxazole-2-carbaldehyde
4,5-dimethyl-2-oxazolecarboxaldehyde化学式
CAS
65128-98-5
化学式
C6H7NO2
mdl
——
分子量
125.127
InChiKey
XHEMOUHXSVJUJF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    228.3±43.0 °C(Predicted)
  • 密度:
    1.140±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    43.1
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    4,5-二甲基噁唑 以50%的产率得到
    参考文献:
    名称:
    Sndler-Kulyk Marija, Vojnovi Dragana, Defterdarovi Nafis, Marini eljko, S+, Heterocycles, 38 (1994) N 8, S 1733-1736
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Formylation of 2,5-Unsubsituted Oxazole: Preparation and Characterization of 2- and 5-Formyl-4-methyloxazoles
    作者:Marija Sindler-Kulyk、Dragana Vojnovic、Nafis Defterdarovic、Zeljko Marinic、Dunja Srzic
    DOI:10.3987/com-94-6693
    日期:——
    Vilsmeier formylation of 4-methyloxazole (1) gave a mixture of 4-methyl-5-oxazolecarboxaldehyde (2) and 4-methyl-2-oxazolecarboxaldehyde (3) in 1:1 ratio. Both aldehydes were prepared unambiguously: aldehyde (2) by oxidation of 5-hydroxymethyl-4-methyloxazole (4) and reduction of chloride of 4-methyl-5-oxazolecarboxylic acid (5) and aldehyde (3) by n-butyllithium/DME procedure. Aldehyde (2) sublimes in a refrigerator while aldehyde (3) forms hydrate, 5-dihydroxymethyl-4-methyloxazole (8).
  • INHIBITORS OF APOL1 AND METHODS OF USING SAME
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20220106327A1
    公开(公告)日:2022-04-07
    The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
查看更多